RÉSUMÉ
OBJECTIVE: To compare the bioavailability and plasma pharmacokinetics of a generic brand of amoxycillin (State Pharmaceutical Manufacturing Coporation) selected from the lower price range, with that of the innovation brand (Amoxil, Beecham). DESIGN: Sixteen healthy adult volunteers were allotted to two groups and each group was given a test dose of amoxycillin from each brand. Blood samples were collected at 0, 2, 3 and 4 hours thereafter plasma levels were assayed using high performance liquid chromatography. RESULTS: Analysis of results show that the generic product had similar bioavailability and pharmacokinetics when compared with the innovator product. CONCLUSION: The quality assured generic amoxycillin tested had similar bioavailability as a more costly branded version.